Zai Lab Past Earnings Performance

Past criteria checks 0/6

Zai Lab's earnings have been declining at an average annual rate of -5%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 45.2% per year.

Key information

-5.0%

Earnings growth rate

1.4%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate45.2%
Return on equity-40.6%
Net Margin-76.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Zai Lab makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:1ZLB Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24356-2712990
30 Jun 24323-298300-9
31 Mar 24291-3392880
31 Dec 23267-3352820
30 Sep 23263-3012710
30 Jun 23252-393269110
31 Mar 23231-4102640
31 Dec 22215-4432590
30 Sep 22197-5932570
30 Jun 22182-5292490
31 Mar 22171-5542400
31 Dec 21144-7042190
30 Sep 21115-569190-160
30 Jun 2187-537159-102
31 Mar 2161-454128-34
31 Dec 2049-2691110
30 Sep 2039-23993192
30 Jun 2029-24083185
31 Mar 2019-20174146
31 Dec 1913-195700
30 Sep 198-21258166
30 Jun 194-18145145
31 Mar 192-16033132
31 Dec 180-13922120
30 Sep 180-891474
30 Jun 180-671453
31 Mar 180-591346
31 Dec 170-501239
30 Sep 170-501041
30 Jun 170-50844
31 Mar 170-44738
31 Dec 160-38632

Quality Earnings: 1ZLB is currently unprofitable.

Growing Profit Margin: 1ZLB is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 1ZLB is unprofitable, and losses have increased over the past 5 years at a rate of 5% per year.

Accelerating Growth: Unable to compare 1ZLB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1ZLB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 1ZLB has a negative Return on Equity (-40.57%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 08:19
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zai Lab Limited is covered by 28 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael MengBOCI Research Ltd.
Linda LuBOCI Research Ltd.
Wai Chak YuenBOCI Research Ltd.